off-the-shelf immune drug for aggressive multiple myeloma: teclistamab
Published 2 years ago • 20K plays • Length 49:38Download video MP4
Download video MP3
Similar videos
-
2:33
teclistamab approval for multiple myeloma treatment | ross firestone, md, phd | asco 2023
-
22:21
tecvayli (teclistamab) everything you need to know
-
11:41
multiple myeloma - signs and symptoms, pathophysiology, treatment
-
14:31
teclistamab - guest lecture
-
8:37
multiple myeloma
-
9:26
what are precursor conditions of multiple myeloma?
-
22:48
my multiple myeloma story: i ignored my symptoms at first | jenny ahlstrom's story
-
1:46
how teclistamab treatment affects quality of life | rakesh popat, md | eha 2022
-
32:28
an "off-the-shelf" approach for myeloma care: bcma antibodies
-
4:03
what are the main classes of drugs used in myeloma?
-
1:46
the complex interplay between the immune microenvironment and tumor cells in multiple myeloma
-
0:45
majestec-2 update: teclistamab plus lenalidomide in r/r multiple myeloma
-
20:12
personalized medicine in multiple myeloma: the latest treatment advancements
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
11:35
what are myeloma targets?
-
56:40
immunotherapy 101 for multiple myeloma patients
-
13:19
using the immune system to fight multiple myeloma
-
1:44
trimm-2: talquetamab daratumumab in patients with r/r multiple myeloma
-
1:00
new treatment approved for multiple myeloma
-
0:59
what is the role of an immune system in a myeloma patient? what is their response to treatment?
-
3:38
are myeloma patients being cured when treated early and aggressively?